ArticleHormones (Athens, Greece)2025
Association between serum albumin levels and risk of deep vein thrombosis in diabetic patients: a retrospective case-control study.
Article in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Parathyroid disease, gut microbiome, biologic age, and more.Hormones (Athens, Greece) · 2025Article
- Parathyroid disease, gut microbiome, biologic age, and more.Hormones (Athens, Greece) · 2025Article
- Development of an interpretable machine learning model for predicting venous thromboembolism in intensive care unit patients with intracerebral hemorrhage.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the predictive value of serum albumin (ALB) levels for deep vein thrombosis (DVT) in diabetic patients, providing a simple and effective biomarker for the early identification of high-risk DVT patients.
methodsA retrospective case-control study was conducted in 133 diabetic patients hospitalized at our hospital between January 2020 and January 2023, including 55 patients diagnosed with DVT (observation group) and 78 patients without DVT (control group). Clinical data, including demographic characteristics, comorbidities, and laboratory indicators (such as serum ALB, HbA1c, HDL, LDL, cardiovascular disease (CVD) history, and insulin treatment) were collected from medical records. Logistic regression analysis was used to identify independent predictors of DVT, adjusting for potential confounding factors, including body mass index (BMI), smoking history, and platelet count. Additionally, the diagnostic performance of serum ALB was assessed using ROC curve analysis in the overall cohort and stratified by CVD status, insulin treatment, and ALB levels.
resultsSerum ALB levels were significantly lower in the DVT group compared to the control group (3.18 ± 0.26 vs. 3.53 ± 0.41 g/L, P < 0.001). Logistic regression confirmed serum ALB as an independent predictor of DVT (univariate OR = 0.070; multivariate OR = 0.076; both P < 0.001). ROC analysis demonstrated good diagnostic performance for serum ALB (AUC = 0.827), with higher accuracy observed in patients with CVD (AUC = 0.885) and those with hypoalbuminemia (AUC = 0.780). Additionally, serum ALB was also a strong predictor for DVT in the insulin-treated subgroup, confirming its diagnostic value across different diabetic subgroups.
conclusionLow serum ALB levels are significantly associated with the occurrence of DVT in diabetic patients. Serum ALB can serve as an effective biomarker for DVT, and regular monitoring can aid in the early identification of high-risk patients and prevent thrombosis.
Indexed as
Identifiers
40540240What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.